Post-marketing surveillance
A great deal of consideration is now being given to the organization of a national scheme in the UK to detect adverse reactions to new drugs which have been granted a product licence and which can be freely prescribed.
Any compound with a biological action has the potential for causing harm as well as good. Before a new drug is given to patients, extensive studies are carried out in various animal species in order to attempt to predict any adverse reactions that might occur in man. However, differences can occur between man and other species in their reactions to drugs. The practolol syndrome, for example, has not been seen in animals; furthermore fenclozic acid, a nonsteroidal anti-inflammatory drug, was found in clinical trials to produce abnormal liver function tests and jaundice which could not be reproduced retrospectively in any of 10 species of animals (Imperial Chemical Industries, personal communication).
Clinical trials are usually carried out in as homogeneous a group of patients as possible in order to determine the safety and efficacy of a new drug compared to placebo or another drug. The patients are monitored very closely and the number that can be studied is obviously limited. Children, pregnant women and patients on other drugs and with other conditions will probably be excluded. Similarly, the length of time for which these patients can be treated is also limitedto treat all the patients for one year means that the trial may last for 3 years. Thus adverse reactions with a low incidence or ones that take some time to develop will not necessarily be picked up by clinical trials.
The more common reactions, such as rash, headache, nausea and so on, will be picked up by clinical trials but it is generally accepted that no amount of pre-clinical and clinical testing will detect all the risks associated with a new drug. At the present time, the detection and recognition of low incidence adverse reactions to marketed drugs relies on reporting by astute physicians mainly by means of publications in medical journals or by their completing 'yellow cards'. The latter are the official forms distributed by the DHSS for reporting adverse reactions. While providing useful information, the current situation is not ideal and serious adverse reactions may not be recognized for some time or it may be difficult to determine their likely frequency.
The detection and reporting of adverse reactions to new drugs was the subject of a symposium held in December 1977 under the auspices of the 0 141-0768/79/010065-02/$O 1.00/0 Medico-Pharmaceutical Forum, of which a report has been published1. Speakers from the medical profession, the DHSS and the pharmaceutical industry discussed their views of the past, present and future situation.
Definitions of the terms used in describing the reporting of adverse reactions varied. The pharmaceutical industry generally regards postmarketing surveillance (PMS) as applying to a scheme operated independently from the industry on a national basis, whereas monitored release indicates a scheme carried out by individual companies on one of their products. Terms other than PMS used for a future national scheme included registered release and recorded release.
The symposium began with a paper by Dr J T Nicholls on the practolol (oculomucocutaneous) syndrome, which described the history and nature of this syndrome and emphasized the difficulty of establishing a definite causal relationship. It was pointed out that the average periods of treatment with practolol before the development of rash, ocular complaints or the signs/symptoms of sclerosing peritonitis were 19.1 months, 25 months or 34 months respectively. Furthermore, sclerosing peritonitis could develop up to 24 months after cessation of therapy. The importance of these factors to any future scheme was recognized.
Since there is currently no official scheme for PMS, some individual pharmaceutical companies have set up special monitoring schemes for their own drugs once they have been granted a product licence. This has been done either voluntarily or as a provision of the licence on the recommendation of the Committee on Safety of Medicines. The speaker from the Association of the British Pharmaceutical Industry described the results of a survey of the experiences of its member companies and found that, in general, there had been many problems with this type of individual follow up. Costs had been high and the data on adverse reactions obtained had been disappointing. The greatest difficulty facing companies had been that of obtaining the cooperation of doctors in completing forms providing information on patients prescribed a new drug. Dr S Shapiro and Dr D Slone, of the Drug Epidemiology Unit in Boston, expressed the view that it was not sufficient to consider PMS in terms of only one or two years following marketing of a ' Post-marketing Surveillance of Adverse Reactions to New Medicines. Medico-Pharmaceutical Forum, new drug, since there may be a long latent period before development of an adverse reaction, as with an unsuspected carcinogen. It should also be possible to relate adverse reactions to different groups of patients such as the fetus, neonate, child, adolescent and adult. The current systems available, such as record linkage, case control surveillance, malformation registries and spontaneous reporting, were described. The problems in relating the incidence of adverse reactions to the incidence of the same reaction in the background population, and the large numbers of patients that would need to be studied, were analysed with examples.
Several speakers put forward their views on a national scheme for PMS. All agreed that there should be a central agency with a computer register of a cohort of patients given a new drug, and that these patients should be followed up at intervals by means of questionnaires to the doctors and possibly to the patients.
Various suggestions were made as to the registration of patients. Information, including the patient's name and address and the type and quantity of the drug, could be transferred from the doctor's prescription to the central agency by the pharmacist or the Prescription Pricing Bureaux at the time of pricing. Alternatively, the prescribing doctor could complete a special form.
It was also agreed that if there were to be positive follow up, then this should be by means of simple questionnaires sent to the doctors at intervals after a patient had been prescribed a new drug. The forms should be designed to detect adverse events as well as adverse reactions. The doctor would be asked to record any unwanted signs or symptoms experienced by the patient, although he might not connect them with the use of the drug. In this way an unexpectedly high incidence of some untoward event could be statistically associated with the drug by the central agency.
Most speakers agreed that any scheme should not, in any way, inhibit doctors' prescribing or the normal promotion of a new drug. The problem of confidentiality of computerized data and the possible implications for litigation were not considered.
Perhaps one-of the most important papers was that given by Mr D Godfrey and Mr E J Bowler, who pointed out how any scheme for PMS could involve very large sums of money, even if only the cost of reimbursing doctors for the extra work involved in completing follow-up forms was taken into account. In addition to this, there would be the cost of registration of patients, by whatever means, the cost of running the central agency and the cost of analysing and validating the data obtained on adverse events.
The meeting was ably chaired and summed up by Sir Richard Doll, Regius Professor of Medicine, Oxford, who expressed the views firstly, that the proposed central agency should be independent from the Licensing Authority; and secondly, that the cost should be borne by the National Health Service and not the manufacturer.
Since this meeting, the Committee on Safety of Medicines has issued a consultative document on PMS which favours registration of patients by way of the Prescription Pricing Authority with, perhaps, three follow-up forms being sent to practitioners. A pilot scheme is to be set up and discussions are taking place with all interested parties.
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Health and the family The threat to the structure of the family in modern society and the recent remarkable growth of family medicine as a discipline formed the background to the Anglo-American Conference, sponsored by the Royal Society of Medicine, The Royal Society of Medicine Foundation, Inc., and the University of Cincinnati, which was held in Cincinnati in May 1978.
Speakers from Britain and the USA, representing the major clinical branches of medicine, the social and behavioural sciences, presented a series of nineteen papers and a panel discussion; this programme dealt in an unusually comprehensive way with the family and its changing status, and the relevance of this to the training of health care professionals and to health care systems.
The keynote paper by Daniels and Smith considered the changing functions of family and the inter-relationship with health and illness. To them it seemed likely that the ordinary and traditional family, the historic values and the usual life styles are less frequent, and that the variability is increased. Health professionals must be ready to respond objectively and without preconceived value judgments to these situations. They should admit of different possibilities for different individuals and be accepting of their patients' explorations and experimentation. Health professionals must be ready to engage the patient where he or she is and try to respond helpfully. At the same time, just as in all other circumstances, they must explore, understand and evaluate the impact of the patients' choices and life style on their adaptation and health. If these choices harm their patients, then their obligation is to communicate that observation. The problem that must be faced is that
